We finally choose 10 new drugs that have never been approved as generic drugs. However, two drugs were pharmaceutical equivalent, a,6) in terms of dissolution profiles(fluvastatin sodium and ezetimibe).
We choose 4 drugs (active ingredients) which were not posted on the US FDA guidance.
3)
We choose 6 active ingredients which were posted on the US FDA guidance.
Twenty drugs were pharmaceutical equivalent products in terms of dissolution profiles that were approved as genetic drugs. Of these, 12 drugs were both pharmaceutical equivalent products and new drugs.
We choose 10 active ingredients which were not posted on the US FDA guidance.
We choose 10 active ingredients based on the data, top 10 lists, for financial burden of drug bills on 2011 from Korean Health Insurance Review & Assessment Service although they were posted on the US FDA guidance. 다양한 데이터 검색기능의 추가 및 사용자 계정 Figure 2 . Draft guidance on cilostazol (example). Pharmaceutical equivalent 6) US FDA Guidance 
